EPAS1 and hereditary clear cell renal cell carcinoma: Belzutifan, an HIF2a inhibitor, has recently been approved by the United States Food and Drug Administration [8] for use in VHL, especially renal cell carcinoma [9], CNS hemangioblastomas, or pancreatic neuroendocrine tumors, not requiring immediate surgery.